Envafolimab plus chemoradiation improves pathologic complete response in MSS rectal cancer

◆ TRIAL DATA

An interim analysis of the phase III PRECAM-R trial found that adding subcutaneous PD-L1 blocker envafolimab to short-course radiotherapy and CAPEOX improved pathologic complete response to 44.8% in patients with microsatellite-stable locally advanced rectal cancer, without clear safety or surgical feasibility penalties. (The ASCO Post)